Japan Intellectual Property Rights: ANTISENSE OLIGOMER FOR TREATMENT OF CONDITION AND DISEASE BASED ON NONSENSE-MEDIATED RNA DEGRADATION MECHANISM

Japan, Jan. 20 -- STOKE THERAPEUTICS INC has got intellectual property rights for 'ANTISENSE OLIGOMER FOR TREATMENT OF CONDITION AND DISEASE BASED ON NONSENSE-MEDIATED RNA DEGRADATION MECHANISM.' Other related details are as follows:

Application Number: JP,2024-015750

Category (FI): A61K31/7088,A61K48/00,A61K45/00,A61K31/712,A61K31/7125,A61P7/00,A61P43/00,105,A61P27/16,A61P27/02,A61P25/28,A61P25/18,A61P25/14,A61P25/08,A61P25/06,C12N15/113@Z,C12N5/10,C12N15/12,C07K14/705,C12N9/12,A61P25/02,A61P25/00,A61P13/12,A61P43/00,121,A61P3/00,A61K38/17

Stage: Grant (IP right document published.)

Filing Date: Feb. 5, 2024

Publication Date: April 23, 2024

The original document can be viewed at: https://www.j-platpat.inpit.go.jp/p0100

Disclaimer: Curated by HT Syndication.